Cerulenin-induced apoptosis is mediated by disrupting the interaction between AIF and hexokinase II

International Journal of Oncology

Volumn 40, Issue 6, 2012, Pages 1949-1956

  Jeong, Na Young ^a   Yoo, Young Hyun ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

AIF; Akt; Cerulenin; Fatty acid synthase; Hexokinase II

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; APOPTOSIS INDUCING FACTOR; CASPASE 3; CERULENIN; CYTOCHROME C; HEXOKINASE; HEXOKINASE ISOENZYME; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; APOPTOSIS REGULATORY PROTEINS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; CERULENIN; CHROMONES; CYTOCHROMES C; DRUG SYNERGISM; HEXOKINASE; HUMANS; MITOCHONDRIA; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84861790189     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1401     Document Type: Article

References (37)

1. Kuhajda FP: Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16: 202-208, 2000.
2. Baron A, Migita T, Tang D and Loda M: Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem 91: 47-53, 2004.
3. Gansler TS, Hardman III W, Hunt DA, Schaffel S and Hennigar RA: Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 28: 686-692, 1997. (Pubitemid 27258421)
4. Liu X, Shi Y, Giranda VL and Luo Y: Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Mol Cancer Ther 5: 494-501, 2006.
5. Pizer ES, Chrest FJ, DiGiuseppe JA and Han WF: Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 58: 4611-4615, 1998. (Pubitemid 28480625)
6. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G and Swinnen JV: RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 63: 3799-3804, 2003. (Pubitemid 36793069)
7. Gabrielson EW, Pinn ML, Testa JR and Kuhajda FP: Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res 7: 153-177, 2001.
8. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB and Dick JD: Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91: 6379-6383, 1994. (Pubitemid 24200664)
9. Pizer ES, Wood FD, Heine HS, Romantsev FR, Pasternack GR and Kuhajda FP: Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56: 1189-1193, 1996. (Pubitemid 26080952)
10. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
11. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A and Testa JR: Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24: 3574-3582, 2005. (Pubitemid 40756227)
12. Yang YA, Han WF, Morin PJ, Chrest FJ and Pizer ES: Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp. Cell Res 279: 80-90, 2002.
13. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G and Swinnen JV: Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 62: 642-646, 2002. (Pubitemid 34126933)
14. Wang D and Sul HS: Insulin stimulation of the fatty acid synthase promoter is mediated by the phosphatidylinositol 3-kinase pathway. Involvement of protein kinase B/Akt. J Biol Chem 273: 25420-25426, 1998. (Pubitemid 28443310)
15. del Peso L, González-García M, Page C, Herrera R and Nuñez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687-689, 1997.
16. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, et al: Hexokinase mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16: 819-830, 2004. (Pubitemid 39586539)
17. Robey RB and Hay N: Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25: 4683-4696, 2006. (Pubitemid 44187618)
18. Mathupala SP, Ko YH and Pedersen PL: Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25: 4777-4786, 2006. (Pubitemid 44187625)
19. Wilson JE: Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 206: 2049-2057, 2003.
20. Cardenas ML, Cornish-Bowden A and Ureta T: Evolution and regulatory role of the hexokinases. Biochim Biophys Acta 1401: 242-264, 1998. (Pubitemid 28122343)
21. Pastorino JG, Hoek JB and Shulga N: Activation of glycogen synthase kinase 3b disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 65: 10545-10554, 2005. (Pubitemid 41743749)
22. Miyamoto S, Murphy AN and Brown JH: Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ 15: 521-529, 2008. (Pubitemid 351267303)
23. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB and Hay N: Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15: 1406-1418, 2001. (Pubitemid 32524647)
24. Pizer ES, Wood FD, Pasternack GR and Kuhajda FP: Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL6O promyelocytic leukemia cells. Cancer Res 4: 745-751, 1996. (Pubitemid 26055462)
25. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH and Tavtigian SV: Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362, 1997. (Pubitemid 27147102)
26. Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S, Yin J, Wang S, Abraham JM, Souza RF, Smolinski KN, Meltzer SJ and Horii A: PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 17: 143-144, 1997.
27. Maier D, Zhang ZW, Taylor E, Hamou MF, Gratzl O, van Meir EG, Scott RJ and Merlo A: Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene 16: 3331-3335, 1998. (Pubitemid 28330433)
28. Bose S, Wang SI, Terry MB, Hibshoosh H and Parsons R: Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 17: 123-127, 1998. (Pubitemid 28360536)
29. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittman M, Tycko B, Hibshoosh H, Wigler MH and Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997. (Pubitemid 27148818)
30. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL and Eng C: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155: 1253-1260, 1999. (Pubitemid 29488932)
31. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP and Mak TW: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39, 1998. (Pubitemid 28458022)
32. Urbano A, Lakshmanan U, Choo PH, Kwan JC, Ng PY, Guo K, Dhakshinamoorthy S and Porter A: AIF suppresses chemical stress-induced apoptosis and maintains the transformed state of tumor cells. EMBO J 24: 2815-2826, 2005. (Pubitemid 41170030)
33. Majewski N, Nogueira V, Robey RB and Hay N: Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cell Biol 24: 730-740, 2004. (Pubitemid 38057924)
34. Heiligtag SJ, Bredehorst R and David KA: Key role of mitochondria in cerulenin-mediated apoptosis. Cell Death Differ 9: 1017-1025, 2002. (Pubitemid 35033433)
35. Kunkel MT, Ni Q, Tsien RY, Zhang J and Newton AC: Spatiotemporal dynamics of protein kinase B/Akt signaling revealed by a genetically encoded fluorescent reporter. J Biol Chem 280: 5581-5587, 2005. (Pubitemid 40280036)
36. Bryson JM, Coy PE, Gottlob K, Hay N and Robey RB: Increased hexokinase activity, of either ectopic or endogenous origin, protects renal epithelial cells against acute oxidant-induced cell death. J Biol Chem 277: 11392-11400, 2002. (Pubitemid 34952906)
37. Lin J, Adam R, Santiestevan E, and Freeman M: The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 59: 2891-2897, 1999. (Pubitemid 29283128)